Adial製藥 ADIL 深 滬
已收盤 04-02 16:00:00 美东时间
1.69
-0.040
-2.31%
華盛通- 最 高1.7499
- 今 開1.69
- 成交量 4.74万股
- 最 低 1.67
- 昨 收 1.73
- 總市值 241.33万
- 52周最高 30.25
- 市盈率 靜 --
- 換手率 3.32%
- 52周最低 1.54
- 委 比 3.85%
- 總股本 142.80万
- 歷史最高 5900.00
- 量 比 0.59
- 振 幅 4.62%
- 歷史最低 1.67
- 每 手 1
- 風險率 4.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
03-24 21:13
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
03-06 21:07
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million
Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.
03-03 21:02
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Super Micro Computer Inc (NASDAQ:SMCI) rose sharply in pre-market tra...
02-04 17:33
Adial Pharmaceuticals Announces 1-For-25 Reverse Stock Split, Effective Feb. 5
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
02-04 05:23
Adial Pharmaceuticals Publishes International Patent Application For AD04 Serotonin-3 Receptor Antagonist Therapeutic Agent To Treat Alcohol Use Disorder
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
01-14 22:03
Adial Pharmaceuticals announces immediate resignation of board director
Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On January 5, 2025, Adi...
01-07 05:50
Adial Pharmaceuticals Secures $2.86M As Investor Exercises 9.2M Warrants At $0.31; Company To Issue 13.8M New Series F Warrants At Same Price
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
2025-11-26 21:04
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals provided a business update and financial results for Q3 2025, highlighting progress on AD04, a Phase 3 drug for Alcohol Use Disorder (AUD). Key milestones include a successful End of Phase 2 meeting with the FDA, advancing toward Phase 3 development, and partnerships with Genomind for precision medicine testing. AD04 targets biomarker-positive AG+ patients, identified via a genetic test. The company's cash reserves were $4.6...
2025-11-14 13:30
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals CEO Cary Claiborne appeared on the Emmy Award-winning Big Biz Show, which aired nationally on Fox Business, NBCUniversal, and Time Warner Cable, as well as globally on 175 countries via radio and streaming platforms. Adial is focused on developing treatments for addiction, with its lead drug AD04 showing promise in reducing alcohol consumption in heavy drinkers and potentially treating other addictive disorders like opioid u...
2025-10-17 13:00
